CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Findings from the Budget Calculator guide you in prioritizing goals and shaping a realistic plan. Use them to steer your financial journey.
20,466 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A cheaper Nasdaq-100 wrapper from Invesco is drawing attention as QQQM tracks the same index with lower fees. The mov...
A director quietly sold a notable stake in American Superconductor, prompting questions about what it signals for inv...
A single, moat-rich stock can anchor a long-term portfolio when you only have $1,500 to invest. This piece explains h...
Millions of workers are surprised to learn a lump-sum move can unlock Net Unrealized Appreciation (NUA) benefits for ...
The energy sector is flashing bright red this year as crude prices recover and producers benefit. This guide dives in...
A risk-off mood is weighing on major cryptos as ETF redemptions surge. This guide breaks down the forces at work and ...
A sharp price drop followed by a sizable insider sale can mean many things. This guide walks through what to watch in...
Camtek reports Q1 2026 revenue of $121.66 million with a booming backlog worth over $260 million for 2026-27, undersc...
As memory cycles swing, the safest play in July may not be the pure-play chips you expect. This article explains why ...
Fermi America slumped 11.5% as it unveiled a $375 million convertible note offering and reported a Q1 with zero reven...
A tariff surge prompts a Monopoly game importer to rethink domestic production. The move highlights the cost, time an...